The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a greater substantial decrease